Ownership and insider activity for Fennec Pharmaceuticals Inc. (FENC): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc.
Price
| Price | $10.55 |
| Market Cap | $366M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-15 | Brughera Marco Maria | M-Exempt | 15,545 | $33K |
| 2026-09-15 | Brughera Marco Maria | M-Exempt | 15,545 | $33K |
| 2026-09-15 | Brughera Marco Maria | S-Sale | 15,545 | $160K |
| 2026-08-31 | Raykov Rosty | A-Award | 2,778 | |
| 2026-09-01 | Raykov Rosty | S-Sale | 10,000 | $121K |
| 2026-08-31 | Sayad Pierre Sargis | A-Award | 168 | |
| 2026-08-31 | Sayad Pierre Sargis | S-Sale | 12,000 | $146K |
| 2026-08-31 | Evans Terry L | A-Award | 168 | |
| 2026-08-31 | Cioffi Christiana Marie | A-Award | 156 | |
| 2026-08-31 | Hackman Jeffrey S. | A-Award | 1,159 |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.9M | $28.3M | $22.8M | $13.7M | $30.3M | $21.1M | $23.8M | $13.3M | $26.6M | $36.7M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | $1.5M | $8.8M | $12.9M | $23.2M |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | $576000 | $2.2M | $1.1M | $1.6M |
| Total Current Assets | $4.0M | $28.4M | $22.9M | $13.9M | $31.4M | $22.4M | $26.7M | $26.9M | $44.1M | $66.6M |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $4.0M | $28.4M | $22.9M | $14.1M | $31.4M | $22.4M | $26.9M | $26.9M | $44.9M | $70.1M |
| Accounts Payable | $244000 | $855000 | $1.0M | $1.6M | $1.6M | $777000 | $2.4M | $3.8M | $3.2M | $4.6M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $402000 | $1.6M | $1.6M | $2.3M | $2.3M | $1.7M | $4.6M | $7.6M | $6.9M | $10.5M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | $5.0M | $24.9M | $30.9M | $19.3M | 0 |
| Total Liabilities | $402000 | $1.6M | $1.6M | $2.3M | $2.3M | $6.6M | $29.5M | $38.5M | $50.8M | $35.0M |
| Retained Earnings | -$114.3M | -$121.4M | -$131.3M | -$144.0M | -$162.1M | -$179.5M | -$203.2M | -$219.2M | -$219.7M | -$229.4M |
| Total Equity | $3.6M | $26.8M | $21.3M | $11.9M | $29.1M | $15.8M | -$2.6M | -$11.6M | -$5.9M | $35.1M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | $5.0M | $24.9M | $31.0M | $19.3M | 0 |
| Net Debt | -$3.9M | -$28.3M | -$22.8M | -$13.7M | -$30.3M | -$16.1M | $1.1M | $17.7M | -$7.3M | -$36.7M |
| Working Capital | $3.6M | $26.8M | $21.3M | $11.6M | $29.1M | $20.7M | $22.1M | $19.3M | $37.2M | $56.1M |
Financial Health
| Piotroski F-Score | 1 |
| Altman Z-Score | 0.49 |
Related companies: AARD · AVTX · BDTX · CRBU · ENTA · EPRX · NAUT
Explore sector: Healthcare · Biotechnology
More sections of FENC: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks